Analytical Data
-
Gene name
LT4R1
- Application
-
Alternative Names
BLT; BLT1; BLTR; CMKRL1; GPR16; P2RY7
-
Species
Human
-
Source
Baculovirus
-
Tag
His;Flag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15722
-
Expression Region
S5-R212, F213-S310, L106W, S116Y, A196I, C287F, S310A
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LT4R1, also known as the human leukocyte antigen (HLA) class I-like molecule, has garnered research interest due to its potential role in immune regulation and response. As a member of the immunoglobulin superfamily, LT4R1 is involved in presenting antigens to T cells, thus influencing the adaptive immune system. Its expression patterns and interactions with other immune cells suggest it may play a crucial role in various diseases, including autoimmune disorders and cancers. Recent studies have focused on its structural characteristics and functional implications, particularly regarding how LT4R1 maintains immune homeostasis and participates in signaling pathways. Understanding LT4R1's mechanism can provide insights into novel therapeutic approaches targeting immune-related conditions, fostering advancements in personalized medicine. Researchers are currently exploring recombinant protein technologies to produce LT4R1 for extensive biochemical assays and potential clinical applications. By elucidating its biological function and interactions, the studies aim to unlock new strategies for modulating immune responses, enhancing vaccine efficacy, and developing effective immunotherapies. This research underscores LT4R1 as a promising candidate for further exploration in the realm of immunology and therapeutic development.
